SCHEMBL822285

SCHEMBL822285

C[Si](C)(Cc1ccccc1)N([Nd](I)N([Si](C)(C)Cc1ccccc1)[Si](C)(C)Cc1ccccc1)[Si](C)(C)Cc1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TAAR1 Q96RJ0 2/20 0.33
AOC3 Q16853 2/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
CASP1 P29466 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP19A1 P11511 1/20 0.32
CALM1 P0DP23 1/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL821353 0.80 PIM1 (0.36) ALDH1A1TSHRTP53KDM4ETDP1
SCHEMBL821913 0.80 CYP19A1 (0.36) ALDH1A1TSHRTP53KDM4ETDP1
SCHEMBL821652 0.80 NR1H2 (0.37) ALDH1A1TSHRTP53KDM4ETDP1
SCHEMBL8777923 0.74 TSHR (0.46) ALDH1A1TSHRTP53TAAR1AOC3
Hydrochloric Acid SCHEMBL821912 0.73 ALDH1A1 (0.37) ALDH1A1TSHRTP53KDM4ETDP1
Iodide SCHEMBL822284 0.69 TSHR (0.37) ALDH1A1TSHRTP53KDM4ETDP1
Iodide SCHEMBL822286 0.69 TSHR (0.37) ALDH1A1TSHRTP53KDM4ETDP1
Hydrochloric Acid SCHEMBL821914 0.69 ALDH1A1 (0.37) ALDH1A1TSHRTP53KDM4ETAAR1
Bromide SCHEMBL821354 0.69 TSHR (0.37) ALDH1A1TSHRTP53KDM4ETDP1
SCHEMBL27884955 0.69 ALDH1A1 (0.41) ALDH1A1TSHRTP53TAAR1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153545-B2 Process for homo—or copolymerization of conjugated olefins STYRON EUROPE GMBH (CH) 2012-04-10 US disclosed
US-20110160041-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS STYRON EUROPE GMBH 2011-06-30 US disclosed
US-7915194-B2 Process for homo- or copolymerization of conjugated olefins STYRON EUROPE GMBH (CH) 2011-03-29 US disclosed
EP-2267046-A1 Process for homo- or copolymerization of conjugated olefines DOW GLOBAL TECHNOLOGIES INC. (US) 2010-12-29 EP disclosed
US-20100248947-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-09-30 US disclosed
US-7612009-B2 Process for homo-or copolymerization of conjugated olefines DOW GLOBAL TECHNOLOGIES, INC. (US) 2009-11-03 US disclosed
US-20060142145-A1 Process for homo-or copolymerization of conjugated olefines TRINSEO EUROPE GMBH (CH) 2006-06-29 US disclosed
EP-1597292-A2 PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES DOW GLOBAL TECHNOLOGIES INC. (US) 2005-11-23 EP disclosed
WO-2004076504-A2 PROCESS FOR HOMO- OR COPOLYMERIZATION OF CONJUGATED OLEFINES DOW GLOBAL TECHNOLOGIES, INC. (US) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160041-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS F12, ETFB, F2 ALDH1A1 3112/4885TSHR 4347/4885TP53 4774/4885
US-20060142145-A1 Process for homo-or copolymerization of conjugated olefines ETFB, F12, F2 ALDH1A1 3114/4885TSHR 4233/4885TP53 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.